Antiretroviral therapy at time of conception associated with some adverse birth outcomes
“If we don’t include women in trials, we are not protecting women” – dolutegravir in pregnant women living with HIV
Aged five, uninfected children of HIV-positive mothers do just as well as children of HIV-negative mothers, South African study shows
Babies of South African mothers taking HIV therapy have worse health in early months – unless they are vaccinated and consistently breastfed
PrEP in pregnancy: safe, but many unanswered questions
Poor physical growth a common problem among HIV-positive adolescents in low- and middle-income countries
Dolutegravir recommended for all in new World Health Organization guidelines
Dolutegravir safety in pregnancy: risk is lower than first reported
Antiretrovirals do not cause neurodevelopmental harm to uninfected infants
